NexgenRx Dividenden en inkoop

Dividend criteriumcontroles 2/6

NexgenRx is een dividendbetalend bedrijf met een huidig rendement van 3.39%.

Belangrijke informatie

3.4%

Dividendrendement

-0.9%

Terugkoop Rendement

Totaal aandeelhoudersrendement	2.5%
Toekomstig dividendrendement	n/a
Dividendgroei	-7.4%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	CA$0.010
Uitbetalingsratio	-2,786%

Recente updates van dividend en inkoop

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: NXG betaalt al minder dan 10 jaar dividend en gedurende deze periode zijn de betalingen volatiel geweest.

Groeiend dividend: NXG betaalt pas 3 jaar dividend uit en sindsdien zijn de betalingen gedaald.

Dividendrendement versus markt

NexgenRx Dividendrendement versus markt

Hoe verhoudt NXG dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (NXG)	3.4%
Markt onderkant 25% (CA)	1.8%
Markt Top 25% (CA)	6.2%
Gemiddelde industrie (Insurance)	3.2%
Analist prognose (NXG) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividend van NXG ( 3.39% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de Canadian markt ( 1.81% ).

Hoog dividend: Het dividend NXG ( 3.39% ) is laag vergeleken met de top 25% van dividendbetalers in de Canadian markt ( 6.18% ).

Winstuitkering aan aandeelhouders

Verdiendekking: NXG keert dividend uit, maar het bedrijf is verliesgevend.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijk lage cash payout ratio ( 41% ) worden de dividendbetalingen van NXG goed gedekt door de kasstromen.

NexgenRx Dividenden en inkoop

Dividend criteriumcontroles 2/6

Belangrijke informatie

Recente updates van dividend en inkoop

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Recent updates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023)

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend